These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17875010)

  • 1. In vivo immunization in combination with peg-interferon for chronic hepatitis B virus infection.
    Sprengers D; van der Molen RG; Binda R; Kusters JG; de Man RA; Niesters HG; Schalm SW; Janssen HL
    J Viral Hepat; 2007 Oct; 14(10):743-9. PubMed ID: 17875010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
    Lu HY; Zhuang LW; Yu YY; Si CW; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
    Schiefke I; Klecker C; Maier M; Oesen U; Etzrodt G; Tannapfel A; Liebert UG; Berr F
    Liver Int; 2004 Apr; 24(2):98-104. PubMed ID: 15078472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.
    Leemans WF; Flink HJ; Janssen HL; Niesters HG; Schalm SW; de Man RA
    J Hepatol; 2006 Mar; 44(3):507-11. PubMed ID: 16457904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B.
    Chan HL; Wong VW; Chim AM; Choi PC; Chan HY; Hui AY; Wong GL; Sung JJ
    Antivir Ther; 2007; 12(5):815-23. PubMed ID: 17713165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
    Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
    Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients.
    Lu HY; Zhuang LW; Yu YY; Si CW
    J Viral Hepat; 2010 Mar; 17 Suppl 1():59-65. PubMed ID: 20586935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B.
    Sarin SK; Sood A; Kumar M; Arora A; Amrapurkar D; Sharma BC; Konar A; Chawla YK; Jain RK; Nanda V; Kumar A; Hissar S; Lavate P; Lahoti D;
    Am J Gastroenterol; 2007 Jan; 102(1):96-104. PubMed ID: 17266689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection.
    Tang TJ; Kwekkeboom J; Mancham S; Binda RS; de Man RA; Schalm SW; Kusters JG; Janssen HL
    J Hepatol; 2005 Jul; 43(1):45-52. PubMed ID: 15893402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virodynamic predictors of response to pegylated interferon and lamivudine combination treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Mihm U; Chan HL; Zeuzem S; Chim AM; Hui AY; Wong VW; Sung JJ; Herrmann E
    Antivir Ther; 2008; 13(8):1029-37. PubMed ID: 19195328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study.
    Villa E; Lei B; Taliani G; Graziosi A; Critelli R; Luongo M; Gennari W; Bianchini M; Ferretti I
    Antivir Ther; 2009; 14(8):1081-7. PubMed ID: 20032538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity.
    Rigopoulou EI; Suri D; Chokshi S; Mullerova I; Rice S; Tedder RS; Williams R; Naoumov NV
    Hepatology; 2005 Nov; 42(5):1028-36. PubMed ID: 16250037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B.
    Akman SA; Okcu SC; Halicioğlu O; Sutcuoglu S; Anil M; Kizilgunesler A; Bakiler AR
    Pediatr Int; 2007 Dec; 49(6):848-52. PubMed ID: 18045284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B.
    Vassiliadis T; Tziomalos K; Patsiaoura K; Zagris T; Giouleme O; Soufleris K; Grammatikos N; Theodoropoulos K; Mpoumponaris A; Dona K; Zezos P; Nikolaidis N; Orfanou-Koumerkeridou E; Balaska A; Eugenidis N
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1582-8. PubMed ID: 17683500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response.
    ter Borg MJ; van Zonneveld M; Zeuzem S; Senturk H; Akarca US; Simon C; Hansen BE; Haagmans BL; de Man RA; Schalm SW; Janssen HL;
    Hepatology; 2006 Sep; 44(3):721-7. PubMed ID: 16941701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment.
    Sarin SK; Kumar M; Hissar S; Sharma BC
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):374-80. PubMed ID: 16911934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients.
    Tang TJ; de Man RA; Kusters JG; Kwekkeboom J; Hop WC; van der Molen RG; Schalm SW; Janssen HL
    J Med Virol; 2004 Feb; 72(2):215-22. PubMed ID: 14695662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study.
    Serfaty L; Thabut D; Zoulim F; Andreani T; Chazouillères O; Carbonell N; Loria A; Poupon R
    Hepatology; 2001 Sep; 34(3):573-7. PubMed ID: 11526544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.
    Chan HL; Hui AY; Wong VW; Chim AM; Wong ML; Sung JJ
    Hepatology; 2005 Jun; 41(6):1357-64. PubMed ID: 15880608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.